Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LESSINA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LESSINA 28.
ENSKYCE vs LESSINA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive